Parmax Pharma Reports Fire Incident at Rajkot Manufacturing Plant

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorIshaan Verma|Published at:
Parmax Pharma Reports Fire Incident at Rajkot Manufacturing Plant

Parmax Pharma Ltd has reported a fire incident at its Rajkot, Gujarat manufacturing facility. While the blaze is under control, the company confirmed two employee injuries and is currently evaluating property damage. The company has stated that assets are covered by insurance, but production impact remains unquantified at this stage. Shareholders should monitor upcoming disclosures regarding operational timelines and the status of insurance recovery processes.

Parmax Pharma Reports Fire Incident at Rajkot Facility

Two employees injured, production impact currently being assessed by management.

Reader Takeaway: The fire is controlled and insured, but production downtime remains the primary uncertainty for investors.

What just happened

Parmax Pharma Ltd reported a fire at its manufacturing plant located on the Rajkot-Gondal National Highway in Hadamtala, Gujarat, on September 28, 2026. The company confirmed that fire-fighting efforts were successful and the situation is now under control.

Safety and Operational Status

Two employees were injured during the incident and have been hospitalized for treatment. No fatalities were reported. The company is currently conducting a formal damage assessment of the site. Specific details concerning the impact on manufacturing output or the duration of potential production downtime have not yet been finalized.

Financial and Insurance

The company has confirmed that the manufacturing facility and its assets are covered under an insurance policy. This provides a financial buffer for reconstruction and asset replacement costs.

What to track next

Investors should look for subsequent exchange filings detailing the exact timeline for resuming full-scale operations. Additionally, the progression of the insurance claim process and any revisions to the company's manufacturing guidance for the current quarter will be critical data points.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.